Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01846923
Recruitment Status : Unknown
Verified May 2013 by Vana Spoulou, Aghia Sophia Children's Hospital of Athens.
Recruitment status was:  Active, not recruiting
First Posted : May 6, 2013
Last Update Posted : May 6, 2013
Sponsor:
Information provided by (Responsible Party):
Vana Spoulou, Aghia Sophia Children's Hospital of Athens

Brief Summary:
The purpose of this study is to determine whether one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) induces immunological memory in asplenic adults and whether previously administered immunizations with the 23-valent polysaccharide pneumococcal vaccine influence the cellular immune response to PCV13 in this group.

Condition or disease Intervention/treatment Phase
Asplenia β-thalassemia Major Biological: PCV13 Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Study of the B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals With Beta-thalassemia Major
Study Start Date : October 2010
Actual Primary Completion Date : February 2012


Arm Intervention/treatment
Experimental: PCV13 Biological: PCV13



Primary Outcome Measures :
  1. immunoglobulin G (IgG) B memory cell response one month post vaccination (measured by ELISpot) [ Time Frame: One month post-PCV13 ]
  2. immunoglobulin M (IgM) B memory cell response one month post vaccination (measured by ELISpot) [ Time Frame: one month post PCV13 ]

Secondary Outcome Measures :
  1. Maintenance of B memory cells three years after PCV13 vaccination [ Time Frame: three years after study vaccination ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Asplenia
  • β-thalassemia major
  • older than 18 years

Exclusion Criteria:

  • no previously recorded allergy to PCV
  • no intravenous immunoglobulin (IVIG) given within the previous 6 months
  • no other vaccine given within the previous 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01846923


Locations
Layout table for location information
Greece
'Aghia Sophia' Children's Hospital
Athens, Attiki, Greece, 11527
Sponsors and Collaborators
Aghia Sophia Children's Hospital of Athens

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Vana Spoulou, Assistant Professor of Paediatrics, Aghia Sophia Children's Hospital of Athens
ClinicalTrials.gov Identifier: NCT01846923     History of Changes
Other Study ID Numbers: 51657MoH
First Posted: May 6, 2013    Key Record Dates
Last Update Posted: May 6, 2013
Last Verified: May 2013

Additional relevant MeSH terms:
Layout table for MeSH terms
Thalassemia
beta-Thalassemia
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn
Heptavalent Pneumococcal Conjugate Vaccine
Immunologic Factors
Physiological Effects of Drugs